Literature DB >> 35267024

Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019.

Priscila M S Castanha1, Dylan J Tuttle1, Georgios D Kitsios2,3,4, Jana L Jacobs5, Ulisses Braga-Neto6, Matthew Duespohl1, Sanjay Rathod7, Michelle M Marti1, Sarah Wheeler8, Asma Naqvi5, Brittany Staines5, John Mellors5, Alison Morris2,4, Bryan J McVerry2,3,4, Faraaz Shah3, Caitlin Schaefer2, Bernard J C Macatangay5, Barbara Methe2,4, Christian A Fernandez7, Simon M Barratt-Boyes1,9, Donald Burke10, Ernesto T A Marques1.   

Abstract

BACKGROUND: Excessive complement activation has been implicated in the pathogenesis of coronavirus disease 2019 (COVID-19), but the mechanisms leading to this response remain unclear.
METHODS: We measured plasma levels of key complement markers, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and antibodies against SARS-CoV-2 and seasonal human common cold coronaviruses (CCCs) in hospitalized patients with COVID-19 of moderate (n = 18) and critical severity (n = 37) and in healthy controls (n = 10).
RESULTS: We confirmed that complement activation is systemically increased in patients with COVID-19 and is associated with a worse disease outcome. We showed that plasma levels of C1q and circulating immune complexes were markedly increased in patients with severe COVID-19 and correlated with higher immunoglobulin (Ig) G titers, greater complement activation, and higher disease severity score. Additional analyses showed that the classical pathway was the main arm responsible for augmented complement activation in severe patients. In addition, we demonstrated that a rapid IgG response to SARS-CoV-2 and an anamnestic IgG response to the nucleoprotein of the CCCs were strongly correlated with circulating immune complex levels, complement activation, and disease severity.
CONCLUSIONS: These findings indicate that early, nonneutralizing IgG responses may play a key role in complement overactivation in severe COVID-19. Our work underscores the urgent need to develop therapeutic strategies to modify complement overactivation in patients with COVID-19.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; and antibodies; classical pathway; common cold coronaviruses; complement system

Mesh:

Substances:

Year:  2022        PMID: 35267024      PMCID: PMC8992249          DOI: 10.1093/infdis/jiac091

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  43 in total

1.  Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania.

Authors:  Glenn J Rapsinski; Megan Culler Freeman; Ghady Haidar; Steven H Belle; Joanne H Hasskamp; Sarah E Wheeler
Journal:  J Clin Virol Plus       Date:  2021-06-09

Review 2.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Authors:  Wen Shi Lee; Adam K Wheatley; Stephen J Kent; Brandon J DeKosky
Journal:  Nat Microbiol       Date:  2020-09-09       Impact factor: 17.745

3.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.

Authors:  Ana Clara Monsalvo; Juan P Batalle; M Florencia Lopez; Jens C Krause; Jennifer Klemenc; Johanna Zea Hernandez; Bernardo Maskin; Jimena Bugna; Carlos Rubinstein; Leandro Aguilar; Liliana Dalurzo; Romina Libster; Vilma Savy; Elsa Baumeister; Liliana Aguilar; Graciela Cabral; Julia Font; Liliana Solari; Kevin P Weller; Joyce Johnson; Marcela Echavarria; Kathryn M Edwards; James D Chappell; James E Crowe; John V Williams; Guillermina A Melendi; Fernando P Polack
Journal:  Nat Med       Date:  2010-12-05       Impact factor: 53.440

4.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.

Authors:  Huan Han; Qingfeng Ma; Cong Li; Rui Liu; Li Zhao; Wei Wang; Pingan Zhang; Xinghui Liu; Guosheng Gao; Fang Liu; Yingan Jiang; Xiaoming Cheng; Chengliang Zhu; Yuchen Xia
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

5.  Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.

Authors:  Aline H de Nooijer; Inge Grondman; Nico A F Janssen; Mihai G Netea; Loek Willems; Frank L van de Veerdonk; Evangelos J Giamarellos-Bourboulis; Erik J M Toonen; Leo A B Joosten
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

6.  Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.

Authors:  György Sinkovits; Blanka Mező; Marienn Réti; Veronika Müller; Zsolt Iványi; János Gál; László Gopcsa; Péter Reményi; Beáta Szathmáry; Botond Lakatos; János Szlávik; Ilona Bobek; Zita Z Prohászka; Zsolt Förhécz; Dorottya Csuka; Lisa Hurler; Erika Kajdácsi; László Cervenak; Petra Kiszel; Tamás Masszi; István Vályi-Nagy; Zoltán Prohászka
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

7.  Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.

Authors:  Jesús F Bermejo-Martin; Milagros González-Rivera; Raquel Almansa; Dariela Micheloud; Ana P Tedim; Marta Domínguez-Gil; Salvador Resino; Marta Martín-Fernández; Pablo Ryan Murua; Felipe Pérez-García; Luis Tamayo; Raúl Lopez-Izquierdo; Elena Bustamante; César Aldecoa; José Manuel Gómez; Jesús Rico-Feijoo; Antonio Orduña; Raúl Méndez; Isabel Fernández Natal; Gregoria Megías; Montserrat González-Estecha; Demetrio Carriedo; Cristina Doncel; Noelia Jorge; Alicia Ortega; Amanda de la Fuente; Félix Del Campo; José Antonio Fernández-Ratero; Wysali Trapiello; Paula González-Jiménez; Guadalupe Ruiz; Alyson A Kelvin; Ali Toloue Ostadgavahi; Ruth Oneizat; Luz María Ruiz; Iria Miguéns; Esther Gargallo; Ioana Muñoz; Sara Pelegrin; Silvia Martín; Pablo García Olivares; Jamil Antonio Cedeño; Tomás Ruiz Albi; Carolina Puertas; Jose Ángel Berezo; Gloria Renedo; Rubén Herrán; Juan Bustamante-Munguira; Pedro Enríquez; Ramón Cicuendez; Jesús Blanco; Jesica Abadia; Julia Gómez Barquero; Nuria Mamolar; Natalia Blanca-López; Luis Jorge Valdivia; Belén Fernández Caso; María Ángeles Mantecón; Anna Motos; Laia Fernandez-Barat; Ricard Ferrer; Ferrán Barbé; Antoni Torres; Rosario Menéndez; José María Eiros; David J Kelvin
Journal:  Crit Care       Date:  2020-12-14       Impact factor: 9.097

8.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

9.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Authors:  Alessandro Sette; Daniela Weiskopf; Jose Mateus; Alba Grifoni; Alison Tarke; John Sidney; Sydney I Ramirez; Jennifer M Dan; Zoe C Burger; Stephen A Rawlings; Davey M Smith; Elizabeth Phillips; Simon Mallal; Marshall Lammers; Paul Rubiro; Lorenzo Quiambao; Aaron Sutherland; Esther Dawen Yu; Ricardo da Silva Antunes; Jason Greenbaum; April Frazier; Alena J Markmann; Lakshmanane Premkumar; Aravinda de Silva; Bjoern Peters; Shane Crotty
Journal:  Science       Date:  2020-08-04       Impact factor: 47.728

10.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Authors:  Kevin W Ng; Nikhil Faulkner; Georgina H Cornish; Annachiara Rosa; Ruth Harvey; Saira Hussain; Rachel Ulferts; Christopher Earl; Antoni G Wrobel; Donald J Benton; Chloe Roustan; William Bolland; Rachael Thompson; Ana Agua-Doce; Philip Hobson; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Kirsty Thomson; Emilie Sanchez; Gee Yen Shin; Moira J Spyer; Dhira Joshi; Nicola O'Reilly; Philip A Walker; Svend Kjaer; Andrew Riddell; Catherine Moore; Bethany R Jebson; Meredyth Wilkinson; Lucy R Marshall; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Coziana Ciurtin; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve J Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis
Journal:  Science       Date:  2020-11-06       Impact factor: 47.728

View more
  2 in total

Review 1.  Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences.

Authors:  Dorota Kamińska; Dominika Dęborska-Materkowska; Katarzyna Kościelska-Kasprzak; Oktawia Mazanowska; Agata Remiorz; Paweł Poznański; Magdalena Durlik; Magdalena Krajewska
Journal:  Vaccines (Basel)       Date:  2022-07-03

Review 2.  Complement activation in COVID-19 and targeted therapeutic options: A scoping review.

Authors:  Endry Hartono Taslim Lim; Rombout Benjamin Ezra van Amstel; Vieve Victoria de Boer; Lonneke Alette van Vught; Sanne de Bruin; Matthijs Christian Brouwer; Alexander Petrus Johannes Vlaar; Diederik van de Beek
Journal:  Blood Rev       Date:  2022-07-30       Impact factor: 10.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.